Skip to content
10-K

Annual Report

ARS Pharmaceuticals, Inc. SPRY

0001193125-26-097478

← back to feed
Filed
Mar 9, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 4, 2026 99.3M sh
Shares Diluted FY 2025 · Dec 31, 2025 98.57M sh
Shares Diluted FY 2025 · Dec 31, 2024 102.39M sh
Capex FY 2025 · Dec 31, 2025 $339K
Capex FY 2025 · Dec 31, 2024 $563K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$170.87M
Operating Cash Flow FY 2025 · Dec 31, 2024 $13.55M
Long Term Debt FY 2025 · Dec 31, 2025 $96.37M
Long Term Debt FY 2025 · Dec 31, 2024 $0
Short Term Investments FY 2025 · Dec 31, 2025 $203.67M
Short Term Investments FY 2025 · Dec 31, 2024 $263.21M
Cash And Equivalents FY 2025 · Dec 31, 2025 $41.32M
Cash And Equivalents FY 2025 · Dec 31, 2024 $50.82M
Stockholders Equity FY 2025 · Dec 31, 2025 $114.26M
Stockholders Equity FY 2025 · Dec 31, 2024 $256.8M
Stockholders Equity FY 2025 · Dec 31, 2023 $230.76M
Current Liabilities FY 2025 · Dec 31, 2025 $39.15M
Current Liabilities FY 2025 · Dec 31, 2024 $23.44M
Total Liabilities FY 2025 · Dec 31, 2025 $213.39M
Total Liabilities FY 2025 · Dec 31, 2024 $94.36M
Current Assets FY 2025 · Dec 31, 2025 $284.9M
Current Assets FY 2025 · Dec 31, 2024 $334.3M
Total Assets FY 2025 · Dec 31, 2025 $327.65M
Total Assets FY 2025 · Dec 31, 2024 $351.15M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.74
Eps Diluted FY 2025 · Dec 31, 2024 $0.08
Eps Basic FY 2025 · Dec 31, 2025 −$1.74
Eps Basic FY 2025 · Dec 31, 2024 $0.08
Sga Expense FY 2025 · Dec 31, 2025 $230.12M
Sga Expense FY 2025 · Dec 31, 2024 $71.68M
Rd Expense FY 2025 · Dec 31, 2025 $13.18M
Rd Expense FY 2025 · Dec 31, 2024 $19.58M
Net Income FY 2025 · Dec 31, 2025 −$171.3M
Net Income FY 2025 · Dec 31, 2024 $8M
Operating Income FY 2025 · Dec 31, 2025 −$179.45M
Operating Income FY 2025 · Dec 31, 2024 −$3.08M
Revenue FY 2025 · Dec 31, 2025 $84.28M
Revenue FY 2025 · Dec 31, 2024 $89.15M